Meda AB
http://www.meda.se/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Meda AB
Finance Watch: Signs Of Life? A Small Offering, Three New Filings And Galderma Hints At An IPO
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Aeglea Revives Fortunes By Joining Merck And Roivant In TL1A Drug Chase
Aeglea looked to be company running out of time, but the reverse merger with Spyre Therapeutics and its TL1A-based inflammatory bowel disease assets could prove to be an inspired move.
Lilly Wants To Gamble On Dice’s Oral IL-17 Drugs For Psoriasis
Lilly agrees to pay about $2.4bn to acquire Dice and its Phase IIb oral IL-17 inhibitor, as well as a discovery platform that has yielded a preclinical oral PD-L1 inhibitor.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Acton Pharmaceuticals, Inc.
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Madaus Pharma
- Rottapharm Madaus
- Meda Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice